Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.

Autoimmune myopathy may be linked to hair loss and skin depigmentation.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

The article presents three clinical cases of universal alopecia developing during TNF-α inhibitor therapy and discusses possible mechanisms and the role of pro-inflammatory cytokines.

This review highlights the need for inclusive dermatology practices to address variations in skin conditions globally by incorporating tools like AI, teledermatology, and culturally competent education.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

This study identified a missense mutation in the human hairless gene associated with a rare form of recessively inherited alopecia universalis, pinpointed on chromosome 8p12.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study identified ABCB6 as the first gene linked to dyschromatosis universalis hereditaria (DUH) in a large Chinese family, suggesting it plays a role in skin pigmentation.

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This case report describes an HIV-infected patient on HAART who developed autoimmune diseases, including alopecia universalis and Graves' disease, associated with immune restoration after CD4 cell count increases.

In this study, serum from patients with alopecia areata or universalis did not affect hair growth in transplanted scalp skin grafts on nude mice, despite increased deposition of immunoreactants.

This article describes a case of dyschromatosis universalis in a young Saudi Arabian girl, discussing similar cases reported outside the Far East where the condition was initially identified, but provides no new research findings.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.

This study reviewed treatment options for alopecia areata totalis and universalis, finding no completely effective therapy. Promising treatments with quality data include diphenylcyclopropenone, squaric acid dibutylester, and photodynamic therapy, but larger, high-quality trials are needed.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This study found that early-onset patients with alopecia universalis or a family history of alopecia areata showed worse prognosis compared to those with late-onset.

This case report describes a woman with alopecia universalis, resistant to multiple treatments, who experienced successful hair regrowth with adalimumab, suggesting potential mechanisms for future investigation.